Patents by Inventor Peter M. Pushko

Peter M. Pushko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20230293667
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.
    Type: Application
    Filed: August 10, 2022
    Publication date: September 21, 2023
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • Modified RSV F proteins and methods of their use
    Patent number: 11446374
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 20, 2022
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 11052146
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 6, 2021
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Functional influenza virus like particles (VLPs)
    Patent number: 10729760
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 4, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Functional influenza virus-like particles (VLPS)
    Patent number: 10548968
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 4, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20200030436
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs)
    Publication number: 20190314484
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Application
    Filed: December 5, 2018
    Publication date: October 17, 2019
    Inventors: Gale SMITH, Rick BRIGHT, Peter M. PUSHKO, Jinyou ZHANG, Kutub MAHMOOD
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20190134187
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 9, 2019
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20190062713
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 28, 2019
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
    Publication number: 20190038738
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Application
    Filed: February 21, 2018
    Publication date: February 7, 2019
    Inventors: Gale SMITH, Rick BRIGHT, Peter M. PUSHKO, Jinyou ZHANG, Kutub MAHMOOD
  • Functional influenza virus like particles (VLPs)
    Patent number: 10188723
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 29, 2019
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Functional influenza virus-like particles (VLPs)
    Patent number: 9956280
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 1, 2018
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs)
    Publication number: 20180110851
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Application
    Filed: May 30, 2017
    Publication date: April 26, 2018
    Inventors: Gale SMITH, Rick BRIGHT, Peter M. PUSHKO, Jinyou ZHANG, Kutub MAHMOOD
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9951317
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20170253861
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 7, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
    Publication number: 20170232095
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Application
    Filed: October 24, 2016
    Publication date: August 17, 2017
    Inventors: Robin A. ROBINSON, Peter M. PUSHKO
  • Modified RSV F proteins and methods of their use
    Patent number: 9731000
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 15, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 9717786
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J Massare, Ye Liu, Gale Smith, Bin Zhou
  • Functional influenza virus like particles (VLPs)
    Patent number: 9694066
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 4, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood